Noninvasive disease monitoring and risk stratification by circulating tumor DNA (ctDNA)
profiling has become a potential novel strategy for patient management in B-cell lymphoma …

Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative
disorders characterized by different clinical courses, varying from indolent to highly …

Purpose: We analyzed the utility of cell-free DNA (cfDNA) in a prospective population-based
cohort to determine the mutational profile, assess tumor burden, and estimate its impact in …

Whether baseline metabolic tumor volume (TMTV) and total lesion glycolysis (TLG)
measured by FDG-PET/CT affected prognosis of patients with lymphoma was controversial …

In the era of precision medicine, it is crucial to identify molecular alterations that will guide
the therapeutic management of patients. In this context, circulating tumoral DNA (ctDNA) …

In this article, we broadly review the application of cfDNA analysis to the diagnosis and
management of lymphoma. We introduce the advantages of cfDNA measurement over …

The relevance of circulating tumor DNA (ctDNA) analysis as a liquid biopsy and minimal
residual disease tool in the management of classical Hodgkin lymphoma (cHL) patients was …

In recent years, the introduction of new molecular techniques in experimental and clinical
settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) …

In the present study, we screened 84 Follicular Lymphoma patients for somatic mutations
suitable as liquid biopsy MRD biomarkers using a targeted next-generation sequencing …

The use of functional quantitative biomarkers extracted from routine PET–CT scans to
characterize clinical responses in patients with lymphoma is gaining increased attention …